FENNEC PHARMACEUTICALS INC.

For the period ended Dec 31, 2025. Filed Mar 27, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 27, 2026

FENC$10.83+10.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations


· · Year Ended
· · December 31, · · December 31,
· · 2025 · · 2024
Revenue
Product sales, net	$44,642	$29,580
Licensing revenue	—	17,958
Total net revenues	44,642	47,538

Operating expenses:
Cost of product sales	3,764	3,184
Research and development	250	307
Selling and marketing	18,616	18,426
General and administrative	28,294	23,053

Total operating expenses	50,924	44,970
(Loss)/income from operations	(6,282)	2,568

Other income/(expense)
Unrealized foreign exchange gain/(loss)	28	(82)
Amortization expense	(64)	(89)
Unrealized loss on securities	(2)	(81)
Loss on debt extinguishment (Note 8)	(2,022)	—
Interest income	787	1,682
Interest expense	(2,080)	(4,069)
Total other expense	(3,353)	(2,639)
Loss before income tax	(9,635)	(71)
Income tax	(106)	(365)
Net loss	$(9,741)	$(436)

Basic net loss per common share	$(0.34)	$(0.02)
Diluted net loss per common share	$(0.34)	$(0.02)
Weighted-average number of common shares outstanding basic	28,577	27,294
Weighted-average number of common shares outstanding diluted	28,577	27,294

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.